Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia.
- DOI
- 10.1093/ejendo/lvag099
- Published
- 2026 Jul 1
- Container
- European journal of endocrinology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ejendo/lvag099,
title = {Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia.},
author = {Beck-Nielsen SS and Ariceta G and Boot AM and Brandi ML and Briot K and de Lucas Collantes C and Emma F and Giannini S and Haffner D and Keen R and Levtchenko E and Nilsson O and Mäkitie O and Mughal MZ and Padidela R and Tripto-Shkolnik L and Zillikens MC and Benchekroun EM and Eltahan E and Joos-Vandewalle P and Melogno-Klinkas M and Schnabel D},
year = {2026},
journal = {European journal of endocrinology},
doi = {10.1093/ejendo/lvag099},
url = {https://doi.org/10.1093/ejendo/lvag099}
}RIS
TY - JOUR TI - Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia. AU - Beck-Nielsen SS AU - Ariceta G AU - Boot AM AU - Brandi ML AU - Briot K AU - de Lucas Collantes C AU - Emma F AU - Giannini S AU - Haffner D AU - Keen R AU - Levtchenko E AU - Nilsson O AU - Mäkitie O AU - Mughal MZ AU - Padidela R AU - Tripto-Shkolnik L AU - Zillikens MC AU - Benchekroun EM AU - Eltahan E AU - Joos-Vandewalle P AU - Melogno-Klinkas M AU - Schnabel D PY - 2026 JO - European journal of endocrinology DO - 10.1093/ejendo/lvag099 UR - https://doi.org/10.1093/ejendo/lvag099 ER -
APA
SS, B., G, A., AM, B., ML, B., K, B., C, D. L. C., F, E., S, G., D, H., R, K., E, L., O, N., O, M., MZ, M., R, P., L, T., MC, Z., EM, B., E, E., P, J., M, M., & D, S. (2026). Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia.. European journal of endocrinology. https://doi.org/10.1093/ejendo/lvag099
Source records
- pubmed · retrieved 2026-09-25T19:57:45.213Z